miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting Nrf2-dependent antioxidant pathway

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 23, 2014, Pages 10439-10444

  Shi, Liang ^a,b   Chen, Zhan Guo ^b   Wu, Li li ^b   Zheng, Jian Jian ^b   Yang, Jian Rong ^b   Chen, Xiao Fei ^b   Chen, Zeng Qiang ^b   Liu, Cun Li ^b   Chi, Sheng Ying ^b   Zheng, Jia Ying ^b   Huang, Hai Xia ^b   Lin, Xiang Yang ^b   Zheng, Fang ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Chemoresistance; Cisplatin; Hepatocellular carcinoma cell lines; MiR 340; Nrf2

Indexed keywords

CISPLATIN; MICRORNA; MIRN340 MICRORNA, HUMAN; NFE2L2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NRF2;

DOWN REGULATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; SIGNAL TRANSDUCTION; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CISPLATIN; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICRORNAS; NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84921804274     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.23.10439     Document Type: Article

References (15)

1. Hsieh MY, Lin ZY, Chen SH, et al (2011). Risk factors for the leakage of chemotherapeutic agents into systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma. Kaohsiung J Med Sci, 27, 431-6.
2. Lavi O, Skinner J, Gottesman MM (2014). Network features suggest new hepatocellular carcinoma treatment strategies. BMC Syst Biol, 8, 88.
3. Gaur A, Jewell DA, Liang Y, et al (2007). Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res, 67, 2456-68.
4. Shi XB, Tepper CG, deVere White RW (2008). Cancerous miRNAs and their regulation. Cell Cycle, 7, 1529-38.
5. Giovannetti E, Erozenci A, Smit J, et al (2012). Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol, 81, 103-22.
6. Hu Q, Gong JP, Li J, et al (2014). Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev, 15, 5137-42.
7. Wang HJ, Guo YQ, Tan G, et al (2013). miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. J Cell Biochem, 114, 2248-57.
8. Yamaguchi T, Nakajima N, Nakamura I, et al (2013). Preclinical anticancer effects and toxicologic assessment of hepatic artery infusion of fine-powder cisplatin with lipiodol in vivo. Drug Discov Ther, 7, 201-8.
9. Yang JX, Luo Y, Qiu HM, et al (2009). Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line. Saudi Med J, 30, 35-40.
10. Chen Y, Fu LL, Wen X, et al (2014). Oncogenic and tumor suppressive roles of microRNAs in apoptosis and autophagy. Apoptosis, 19, 1177-89.
11. Robertson NM, Yigit MV (2014). The role of microRNA in resistance to breast cancer therapy. Wiley Interdiscip Rev RNA.
12. Bao LJ, Jaramillo MC, Zhang ZB, et al (2014). Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Int J Clin Exp Pathol, 7, 1502-13.
13. Niture SK, Kaspar JW, Shen J, et al (2010). Nrf2 signaling and cell survival. Toxicol Appl Pharmacol, 244, 37-42.
14. Sangokoya C, Telen MJ, Chi JT (2010). microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood, 116, 4338-48.
15. He X, Ma Q (2010). Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic sensing and suppression of nuclear factor erythroid 2-related factor 2. J Pharmacol